Atlas Venture Life Science Advisors’s Kymera Therapeutics KYMR Stock Holding History

Atlas Venture Life Science Advisors’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$327M	Sell	2,847,541 -1,730,467	-38%	-$149M	37.05%	1
2026 Q1	$381M	Sell	4,578,008 -81,866	-2%	-$6.48M	48.26%	1
2025 Q4	$363M	Sell	4,659,874 -236,588	-5%	-$16M	41.91%	1
2025 Q3	$277M	Hold	4,896,462	–	–	36.82%	1
2025 Q2	$214M	Hold	4,896,462	–	–	32.26%	1
2025 Q1	$134M	Hold	4,896,462	–	–	25.69%	1
2024 Q4	$197M	Hold	4,896,462	–	–	24.03%	1
2024 Q3	$232M	Sell	4,896,462 -453,960	-8%	-$20M	21.48%	2
2024 Q2	$160M	Sell	5,350,422 -26,940	-0.5%	-$933K	16.82%	2
2024 Q1	$216M	Sell	5,377,362 -480,900	-8%	-$17.2M	19.95%	2
2023 Q4	$149M	Hold	5,858,262	–	–	17.76%	1
2023 Q3	$81.4M	Hold	5,858,262	–	–	12.61%	4
2023 Q2	$135M	Hold	5,858,262	–	–	16.76%	2
2023 Q1	$174M	Sell	5,858,262 -126,474	-2%	-$4.08M	23.5%	1
2022 Q4	$149M	Sell	5,984,736 -890,962	-13%	-$23.8M	17.99%	2
2022 Q3	$150M	Hold	6,875,698	–	–	16.52%	3
2022 Q2	$135M	Hold	6,875,698	–	–	22.63%	2
2022 Q1	$291M	Hold	6,875,698	–	–	36.79%	1
2021 Q4	$437M	Buy	+6,875,698	New	+$400M	40.09%	1

Other funds holding KYMR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Atlas Venture Life Science Advisors's KYMR Position: Q2 2026 in Review

Atlas Venture Life Science Advisors reduced its Kymera Therapeutics (KYMR) stake by 38% in Q2 2026, selling an estimated $149M and leaving 2,847,541 shares worth $327M. The position accounts for 37.05% of the portfolio, ranked #1.

Atlas Venture Life Science Advisors first reported a position in KYMR in Q4 2021 and has held it in 19 quarters since. The position peaked at $437M in Q4 2021. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

Atlas Venture Life Science Advisors held 2,847,541 shares of Kymera Therapeutics worth $327M as of Q2 2026.
Atlas Venture Life Science Advisors sold 1,730,467 Kymera Therapeutics shares in Q2 2026, an estimated $149M.
Kymera Therapeutics made up 37.05% of Atlas Venture Life Science Advisors's portfolio in Q2 2026, its #1 holding.
Atlas Venture Life Science Advisors first reported a position in Kymera Therapeutics in Q4 2021 and has held it in 19 quarters since.
Atlas Venture Life Science Advisors's Kymera Therapeutics position peaked at $437M in Q4 2021.
276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Atlas Venture Life Science Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.